Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lupus pill shows promise in major trial

NCT ID NCT05672576

Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 6 times

Summary

This Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activity index.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cenerimod
What this could lead to
If successful, cenerimod could become a new treatment option to better control lupus symptoms and reduce disease flares.
What could go wrong
This is still an experimental drug. Even in Phase 3, it may not work better than placebo, and side effects are possible. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

451 people

The number who actually took part.

Started

Jun 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria at screening: * Signed Informed Consent Form (ICF) prior to any study-mandated procedure. * Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria. * A modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not include "leukopenia". * British Isles Lupus Assessment Group-2004 (BILAG) Grade B in ≥ 2 organ systems or a BILAG Grade A in ≥ 1 organ system. * Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 visual analog scale. * Currently treated with one or more of the following SLE background medications: * Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine). * Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤1.44 g/day). * Azathioprine (≤ 2 mg/kg/day). * Methotrexate (≤ 25 mg/week). * Oral Corticosteroids (OCS): * if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent. * if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent. * Belimumab (≤10 mg/kg every 4 weeks intravenously \[i.v.\], or 200 mg/week subcutaneously \[s.c.\]). Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening. • For women of childbearing potential (WoCBP): * Negative serum pregnancy test at Screening. * Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation. * Agreement to use a highly effective method of contraception from Screening (Visit 1) up to 6 months after study treatment discontinuation. Inclusion criteria at randomization: * A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). * BILAG Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system. * PGA score ≥ 1.0 on a 0 to 3 visual analog scale. * Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory): * Anti-dsDNA antibodies elevated above normal, * Antinuclear antibodies with a titer of at least 1:160, * Anti-Smith antibody elevated above normal. * Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization): * Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine); * Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44g/day); * Azathioprine (≤ 2 mg/kg/day); * Methotrexate (≤ 25 mg/week); * OCS: * if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent. * if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent. * Belimumab (≤ 10 mg/kg every 4 weeks i.v. or ≤ 200 mg/week s.c.). * WoCBP must have a negative urine pregnancy test at Randomization. Main Exclusion Criteria: * Pregnant, planning to be become pregnant up to Final Study Visit, or lactating women. * Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex: * That would make the subject unable to fully understand the ICF; OR * Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated. * A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, autoimmune hepatitis or uncontrolled autoimmune thyroid disease. * History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders. * Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within 6 months prior to Screening. * Resting heart rate \< 50 bpm as measured by the 12-lead ECG at Screening or at Randomization. * An elevated QT interval corrected according to Fridericia's formula (QTcF) interval of \> 470 ms (females) / \> 450 ms (males) at Screening or at Randomization. * History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening. * History of clinically relevant bronchial asthma or chronic obstructive pulmonary disease that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening. * History or presence of malignancy (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening. * Presence of any of the following abnormalities detected during the ophthalmological evaluation and/or by optical coherence tomography (OCT) during screening: * Macular edema of any cause: diabetic, cystoid, tractional. * Foveal degeneration, macular hole, macular pseudohole, hereditary or degenerative maculopathies. * Active uveitis, papilledema. * Retinal neovascularization of any cause and in any location. * History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with alanine aminotransferase or aspartate aminotransferase \> 3 × Upper Limit of Normal (ULN) or total bilirubin \> 1.5 × ULN (unless in the context of known Gilbert's Syndrome). * Significant hematology abnormality at screening assessment: * lymphocyte count \< 500 /μL (0.5 × 10\^9/L); * hemoglobin \< 7 g/dL; * white blood cell count \< 2000/μL (2.0 × 10\^9/L); or * platelets \< 25000/μL (25 × 10\^9/L). * Estimated glomerular filtration rate \< 15 mL/min/1.73 m\^2. * Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other antiarrhythmic or heart-rate -lowering systemic therapy. * QT-prolonging drugs with known risk of torsade de pointes irrespective of indication. * Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc. * Pulse methylprednisolone. * Vaccination with live vaccines (including live vaccines for COVID-19). * Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization. * Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: * Leflunomide. * i.v. immunoglobulins. * Treatment with any investigational agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization. * Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological immunosuppressive agents (e.g., anti-tumor necrosis factor \[TNF\], anti-interleukin \[IL\]-1, anti-IL6 therapies), within 12 months prior to Randomization. * Treatment with anifrolumab within 6 months prior to Randomization. * Treatment with any of the following medications any time prior to Screening: * Alemtuzumab, * Sphingosine-1-phosphate receptor modulators (e.g., fingolimod), * Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus erythematosus, systemic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease connective tissue disorder immune system disorder systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus erythematosus, systemic

Contacts and locations

Locations

  • "Medbud-Clinic" LLC, Treatment and Prevention Department of the Medical Center

    Kyiv, 03037, Ukraine

  • "Medical Center Health Clinic" LLC, Medical Clinical Investigational Center, Department of Cardiology and Rheumatology

    Vinnytsia, 21009, Ukraine

  • AIIMS New Delhi

    New Delhi, 110029, India

  • Accelerium, S. de R.L. de C.V.

    Monterrey, 64000, Mexico

  • Accellacare

    Alcobendas, 28100, Spain

  • Alberto Sabogal Sologuren National Hospital

    Lima, 07011, Peru

  • Allied Biomedical Research Institute

    Miami, Florida, 33155, United States

  • Alloy Clinical Research, LLC

    Kissimmee, Florida, 34741, United States

  • Amicis Research Center

    Northridge, California, 91234, United States

  • Arthritis Clinical Research Trials

    Cape Town, 7405, South Africa

  • Aversi Clinic LTD

    Tbilisi, 0160, Georgia

  • Biomedica Research Group

    Providencia, 7500710, Chile

  • Boca Clinical Trials Mexico, S.C.

    Mexico City, 01120, Mexico

  • Caucasus Medical Centre

    Tbilisi, 0186, Georgia

  • Center for Rheumatic Diseases

    Pune, 411001, India

  • Centro Hospitalar Universitário do Algarve - Hospital de Faro

    Faro, 8000-386, Portugal

  • Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

    Vila Nova de Gaia, 4434-502, Portugal

  • Centro Integral en Reumatologia SA de CV (CIRSA)

    Guadalajara, 44160, Mexico

  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P. (CEMDEICY S.C.P.)

    Mérida, 97130, Mexico

  • Centro Reumatologico de Caguas

    Caguas, 00725, Puerto Rico

  • Centro de Especialidades Medicas Vanguardia

    Temuco, 4810345, Chile

  • Centro de Estudios Clínicos de Querétaro S.C.

    Querétaro, 76000, Mexico

  • Centro de Investigacion Clinica Inmunoreumatologia / ACQ Medic SAC

    Jesús María, 15076, Peru

  • Centro de Investigación Clínica GRAMEL, S.C.

    Mexico City, 03720, Mexico

  • Centro de Investigación Clínica Trujillo EIRL / Clínica Peruano Americana S.A

    Trujillo, 13011, Peru

  • Centro de Investigación del Hospital Militar Central

    Jesús María, 15076, Peru

  • Charlotte Maxeke Johannesburg Academic Hospital

    Parktown, 2193, South Africa

  • Chennai Meenakshi Multispeciality Hospital Pvt. Ltd.

    Chennai, 600004, India

  • Chopda Medicare & Research Centre

    Nashik, 422005, India

  • Clinica Gaias Santiago

    Santiago de Compostela, 15702, Spain

  • Clinical Center Kragujevac

    Kragujevac, 34000, Serbia

  • Clinical Research Chile SpA

    Valdivia, 5110683, Chile

  • Clinical Research Institute S.C.

    Tlalnepantla, 54055, Mexico

  • Clinstile, S.A. de C.V.

    Mexico City, 06700, Mexico

  • Clínica Anglo Americana

    San Isidro, 15073, Peru

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Communal Non-Com Entr Vinnytsia City Clin Hpt 1, Clin Therapy Dprt 2, Vinnytsia Nat Pirogov Memo Med Uni, Dprt of Internal Med 3

    Vinnytsia, 21029, Ukraine

  • Communal Non-profit Enterprise "Chernihiv Regional Hospital" of the Chernihiv Regional Council, Rheumatology Department

    Chernihiv, 14029, Ukraine

  • Consultorio Particular Dr. Miguel Cortés Hernández

    Cuernavaca, 62448, Mexico

  • D&H National Research Centers INC

    Miami, Florida, 33155, United States

  • ESIC Medical College and Hospital

    Hyderabad, 500038, India

  • Enroll SpA

    Santiago, 7500587, Chile

  • Estudios G y C Ltda

    Santiago, 7500504, Chile

  • Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP

    Frankfurt am Main, 60596, Germany

  • GCM Medical Group, PSC

    San Juan, 917, Puerto Rico

  • General Hospital "Djordje Joanovic"

    Zrenjanin, 23000, Serbia

  • Guy's and St. Thomas' NHS Foundation Trust - Guy's Hospital

    London, SE1 9RT, United Kingdom

  • Hope Clinical Trials, Inc.

    Coral Gables, Florida, 33134, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Maria Auxiliadora

    Lima, 15828, Peru

  • Hospital Nacional Cayetano Heredia

    San Martín de Porres, 15102, Peru

  • Hospital Prof. Doutor Fernando Fonseca

    Amadora, 2720-276, Portugal

  • Hospital QuironSalud Sagrado Corazon

    Seville, 41013, Spain

  • Hospital San José de Victoria

    Victoria, 4720001, Chile

  • Hospital Selayang

    Batu Caves, 68100, Malaysia

  • Hospital Senhora Oliveira-Guimaraes

    Guimarães, 4835-044, Portugal

  • Hospital Sibu, Sarawak

    Sibu, 96000, Malaysia

  • Hospital Tuanku Fauziah, Kangar

    Kangar, 01000, Malaysia

  • Hospital Universitari Vall d'Hebron

    Colmenar Viejo, 08035, Spain

  • Hospital Universitario Doctor Peset

    Valencia, 46017, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, 28031, Spain

  • Hospital Universitario Nuestra Señora de Valme

    Seville, 41014, Spain

  • Hospital Universitario Ramon y Cajal

    Colmenar Viejo, 28770, Spain

  • Hospital Universitario Río Hortega de Valladolid

    Valladolid, 47012, Spain

  • IPGME&R and SSKM Hospital

    Kolkata, 700020, India

  • Iloilo Doctors Hospital

    Iloilo City, 5000, Philippines

  • Institute of Clinical Cardiology, Ltd

    Tbilisi, 0159, Georgia

  • Institute of Rheumatology Prague

    Prague, 12800, Czechia

  • Institute of Rheumatology, Belgrade (study site 1)

    Belgrade, 11000, Serbia

  • Institute of Rheumatology, Belgrade (study site 2)

    Belgrade, 11000, Serbia

  • Institute of Rheumatology, Belgrade (study site 3)

    Belgrade, 11000, Serbia

  • Instituto Peruano del Hueso y la Articulación S.A.C. (IPHAR)

    San Isidro, 15046, Peru

  • Instituto Portugues De Reumatologia

    Lisbon, 1050-034, Portugal

  • Investigaciones Clinicas / Instituto de Ginecología y Reproducción, El Derby

    Santiago de Surco, 15023, Peru

  • JSC Jerarsi Clinic

    Tbilisi, 0167, Georgia

  • Jasleen Hospital

    Nagpur, 440012, India

  • Johannes Wesling Klinikum Minden

    Minden, 32429, Germany

  • LLC "Innova"

    Tbilisi, 0186, Georgia

  • LLC Raymann

    Tbilisi, 0186, Georgia

  • LTD "New Plasma Clinic"

    Batumi, 6010, Georgia

  • LTD "Tbilisi Central Hospital"

    Tbilisi, 0159, Georgia

  • LTD "Tbilisi Heart Center"

    Tbilisi, 0186, Georgia

  • Limited Liability Company "Medical Centre 'Consilium Medical'", Clinical and Consultation Department

    Kyiv, 04050, Ukraine

  • Ltd. Mtskheta Street Clinic

    Tbilisi, 0179, Georgia

  • MICS Centrum Medyczne Warszawa

    Warsaw, 00-874, Poland

  • Makati Medical Center

    Makati, 1229, Philippines

  • Med Center "Ok!Clinic+" of Ltd Liability Com "Inter Ins of Clin Rsrch", Inpatient dprt, Unit of Ther, Rheuma and Cardio

    Kyiv, 02091, Ukraine

  • Medi Club Georgia Ltd.

    Tbilisi, 0160, Georgia

  • Medical Center "Center of Family Medicine Plus" LLC, Treatment and Prevention Department

    Kyiv, 04210, Ukraine

  • Medical Center "Harmoniia krasy", LLC

    Kyiv, 01135, Ukraine

  • Medical Center "Universal Clinic "Oberih"" of Limited Liability Company "Capital"

    Kyiv, 03057, Ukraine

  • Medical Center of the Limited Liability Company "Edelweiss Medics", Treatment and Prevention Department

    Kyiv, 02002, Ukraine

  • Medyczne Centrum Hetmańska

    Poznan, 60-218, Poland

  • Military Medical Academy

    Belgrade, 11040, Serbia

  • Morales Vargas Centro de Investigación S.C.

    León, 37000, Mexico

  • National Institute of Endocrinology Ltd.

    Tbilisi, 0159, Georgia

  • Nirmal Hospital Private Limited

    Surat, 395002, India

  • Northwest Houston Arthritis Center

    Houston, Texas, 77090, United States

  • Oaxaca contra el Cáncer A.C

    Oaxaca City, 68000, Mexico

  • Ospital ng Makati

    Makati City, 1218, Philippines

  • PCR Toluca - Phylasis Clinical Research

    Toluca, 50090, Mexico

  • Panorama Medical Centre

    Cape Town, 7500, South Africa

  • Parc Tauli Sabadell University Hospital

    Barcelona, 08208, Spain

  • Pomorski Uniwersytet Medyczny w Szczecinie

    Szczecin, 71-252, Poland

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas, 76034, United States

  • Professional research Center INC

    Miami, Florida, 33172, United States

  • RB Wellness Clinic

    Las Vegas, Nevada, 89102, United States

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida, 33014, United States

  • Santa Sp. z o.o.

    Lodz, 90-302, Poland

  • Sarawak General Hospital

    Kuching, 93586, Malaysia

  • Servicios Reumatológicos SOMA E.I.R.L. / Clinica El Golf

    San Isidro, 15076, Peru

  • Shalby Hospitals

    Ahmedabad, 380015, India

  • Sociedad Médica del Aparato Locomotor S. A.

    Providencia, 7510186, Chile

  • Special Hospital for Rheumatic Diseases, Novi Sad

    Novi Sad, 21000, Serbia

  • St Luke's Medical Center Quezon City / University of Santo Tomas Hospital

    Sampaloc, 1015, Philippines

  • St Lukes Medical Center

    Manila, 1102, Philippines

  • St. Luke's Treatment and Diagnostic Center

    Ivano-Frankivsk, 76019, Ukraine

  • Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy

    Bydgoszcz, 85-168, Poland

  • Tandem Clinical Research

    Marrero, Louisiana, 70072, United States

  • Tbilisi Heart and Vascular Clinic Ltd.

    Tbilisi, 0159, Georgia

  • Tbilisi Institute of Medicine

    Tbilisi, 0160, Georgia

  • Tectum Medical Research

    Hollywood, Florida, 33024, United States

  • Ternopil Regional Clinical Hospital

    Ternopil, 46002, Ukraine

  • Texas Arthritis Center

    El Paso, Texas, 79902, United States

  • The First Medical Center Ltd.

    Tbilisi, 0180, Georgia

  • The Medical City Clark

    Pampanga, 2023, Philippines

  • Tucson Clinical Research Institute, LLC

    Tucson, Arizona, 85712, United States

  • Twoja Przychodnia Poznańskie Centrum Medyczne

    Poznan, 61-293, Poland

  • UBAM Unidad Biomédica Avanzada Monterrey

    Monterrey, 64460, Mexico

  • UCSD Perlman Medical Offices

    La Jolla, California, 92037-0943, United States

  • ULS Guarda

    Guarda, 6300-749, Portugal

  • Unidad de Investigación de la Clinica International

    San Borja, 15036, Peru

  • Unidad de Investigación en Medicina Interna y Enfermedades Críticas / Hogar Clínica San Juan de Dios

    Cayma, 04017, Peru

  • Unidad de Investigación en Reumatología e Inmunología CSJB

    San Juan de Lurigancho, 15431, Peru

  • Unidade Local De Saude Lisboa Ocidental E.P.E.

    Lisbon, 1349-019, Portugal

  • Universiti Kebangsaan Malaysia - Medical Centre

    Cheras, 56000, Malaysia

  • University Clinical Center of Serbia

    Belgrade, 11000, Serbia

  • University Hospitals of Leicester Nhs Trust

    Leicester, LE5 4PW, United Kingdom

  • University of Malaya Medical Centre

    Kuala Lumpur, 59100, Malaysia

  • University of Pretoria

    Pretoria, 0002, South Africa

  • Universitätsklinikum Leipzig

    Leipzig, 4103, Germany

  • Universitätsklinikum Münster (UKM)

    Münster, 48149, Germany

  • Vital Pharma Research

    Hialeah, Florida, 33016, United States

  • Winelands Medical Research

    Somerset West, 7130, South Africa

  • Yashoda Hospital

    Secunderabad, 500003, India

  • iMedica s.r.o.

    Brno, 60200, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.